Condition: Waldenström's Macroglobulinemia · Chronic Lymphocytic Leukemia · Marginal Zone Lymphoma · Sponsor: iOMEDICO AG
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.
This description comes directly from the study's public registry record.
Daniel Kummer, Dr. · +49761152420 · ariadne@iomedico.com
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Salzburg, Klinik für Innere Medizin III | Salzburg, Austria | Recruiting |
| Lübecker Onkologische Schwerpunktpraxis | Lübeck, Schleswig-Holstein, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05326308